ClinicalTrials.gg
RecruitingNCT06162780Updated Mar 15, 2024

TEER for Severe DMR of Low to Intermediate Surgery Risk

An observational study in Mitral Regurgitation, sponsored by Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-03-15.

Sponsored by Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Observational

How we know

From the registry’s dates

  • Started Jan 2024; still recruiting 2 years 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Prospective
Enrollment
160
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 57 studies in Mitral Valve Insufficiency with a site in China — 44 open to participants now, 46 under way, none of them phase 3. Mitral Valve Insufficiency · China.

Planned enrollment
16th of 17
160 · median 1,000
Started
2024
with 6 others
Observational
17 of 57
12 open now
Primary completion
2026-12
later than 25 of 45 live
Registered
27th of 57
by date
Lead sponsor
3 of 57
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Among the 57 studies in Mitral Valve Insufficiency with a site in China, this one is the 16th largest by planned enrollment of the 17 observational ones that give a count, is one of 7 that started in 2024, is one of 17 observational ones, reaches primary completion later than 25 of the 45 other live ones, and was the 27th registered.

Mitral Valve Insufficiency

471 studies on the registry are indexed under Mitral Valve Insufficiency; 165 are open to participants now.

Browse Mitral Valve Insufficiency studies →

Open to participants now

44 of the 57 studies in Mitral Valve Insufficiency with a site in China are open now. Recruiting first, the newest first:

38 more — sign in →

All 44 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 121 Mitral Valve Insufficiency studies recruiting now, 100 (83%) set no upper age limit and 6 (5%) stop at 75 or younger; 12 take children under 18; 1 takes healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 57 studies in Mitral Valve Insufficiency with a site in China, or all of them as a file.
02

Study summary

To investigate the efficacy and safety of transcatheter mitral valve edge-to-edge repair (TEER) for severe degenerative mitral regurgitation (DMR) patients of low to intermediate surgery risk.

Read the detailed description

This is a proposed multicentre, prospective cohort study to enrol and follow up severe DMR patients of low to intermediate surgery risk who underwent TEER, and surgical historical controls. The primary efficacy endpoints are all-cause death and cumulative composite event rate of worsening heart failure at 24 months postoperatively, and the primary safety endpoints are death, secondary surgery, and various complications at 30 days postoperatively. The study aims to investigate the efficacy and safety of TEER in surgical low-intermediate-risk patients with severe DMR, and to inform the subsequent clinical application.

03

Conditions studied

  • Mitral Regurgitation

Keywords

  • degenerative mitral regurgitation
  • transcatheter mitral valve edge-to-edge repair
  • surgery risk
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

severe DMR patients of low to intermediate surgery risk who underwent TEER.

Eligibility criteria

Inclusion Criteria: the patient fully meets the following criteria.

  1. age ≥ 18 years old
  2. DMR ≥ grade 3+ according to UCG integrative approach, referring to the following quantitative indicators: 1) effective regurgitant orifice area (EROA) ≥0.3cm\^2; 2) regurgitant volume (RVol) ≥45ml; 3) regurgitant fraction (RF) ≥40%.
  3. symptomatic heart failure ( (NYHA) class II-IV ), or asymptomatic heart failure with left ventricular end systolic dimension (LVESd) ≥40mm or (EF) ≤60%, or new-onset atrial fibrillation, or resting pulmonary artery systolic pressure (PASP) >50mmHg.
  4. The patient with American Association of Thoracic Surgeons Score (STS) \<8 has surgical indications evaluated by cardiac team.
  5. The patient has signed an form and agreed to regular follow-up for at least 1 year.

Exclusion Criteria: the patient meets any of the following criteria.

  1. active infective endocarditis especially occurring in the mitral valve area, or mitral valve perforation.
  2. rheumatic mitral valve disease, mitral stenosis or mitral valve orifice area \< 4mm\^2.
  3. combined valve lesions requiring surgery, e.g. severe tricuspid regurgitation or aortic valve disease.
  4. the present of tumour, thrombus or redundant organisms in the heart chambers.
  5. inability to tolerate intraoperative or postoperative antithrombotic (anticoagulant or antiplate) therapy.
  6. acute DMR, e.g. DMR caused by acute papillary muscle rupture.
  7. Due to the presence of certain anatomical conditions, patient has a low success rate for TEER assessed by the operator and is not appropriate for enrolment. The conditions include but are not limited to the followings: 1) the venous approach is not suitable for operation, such as thrombus in the approach and small vein diameter; 2) severe calcification presents in the flap leaflet clamping area; 3) mitral valve cleft; 4) multiple regurgitant flow, especially in the internal and external union junction area; 5) Barlow disease; 6) leaflet length \<7mm; 7) flail gap >10mm; 8) flail width >15mm.
  8. severe cardiac insufficiency ( NYHA class IV or lefr ventricular ejection fraction (LVEF) \<20% ), end-stage heart failure status ( American College of Cardiology/American Heart Association (ACC/AHA) Stage D), relying on circulation aids or waiting for heart transplantation.
  9. proposed implantation of heart failure device such as cardiac resynchronization therapy/cardiac resynchronization therapy defibrillator (CRT/CRT-D) or cardiac contractility modulation (CCM).
  10. untreated severe coronary artery stenosis requiring coronary revascularization, or other cardiac macrovascular disease requiring surgery.
  11. hypertrophic cardiomyopathy, restrictive cardiomyopathy, constrictive pericarditis, or structural heart disease leading to heart failure other than dilated heart disease.
  12. severe pulmonary hypertension ( PASP >70 mmHg), or pulmonary hypertension associated with no-left heart disease, e.g. pulmonary arterial hypertension (PAH) etc.
  13. acute myocardial infarction within 4 weeks before operation.
  14. acute cerebrovascular accident within 30 days before operation.
  15. acute peptic ulcer or upper gastrointestinal bleeding within 3 months before operation.
  16. uncontrolled hyperthyroidism.
  17. uncontrolled connective tissue diseases especially Behcet's disease and systemic lupus erythematosus (SLE).
  18. amyloidosis.
  19. severe infections, septicaemia.
  20. severe hepatic insufficiency, e.g. acute severe hepatitis, decompensated cirrhosis ( class C)
  21. severe renal insufficiency ( chronic kidney disease (CKD) stage 5: estimated (eGFR) \< 15 ml/min or dialysis).
  22. hypotensive state, shock ( systolic blood pressure \< 90mmHg or mean arterial pressure \<70 mmHg with tissue hypoperfusion and urine output \< 30 ml/h).
  23. uncontrolled diseases of the haematological system: acute gastrointestinal bleeding, intracranial haemorrhage or haemorrhage from other organs, acute pulmonary embolism or deep vein thrombosis, congenital or acquired haemorrhagic disease such as haemophilia, anaphylactic purpura and acute leukaemia, severe abnormalities in haematological parameters such as count \<20*10\^9/L and (INR) >3.
  24. for TEE, e.g. oesophageal constriction, oesophageal tumour, oesophageal fistula, oesophageal varices, cervical vertebral instability, etc.
  25. contraindication for intravenous anaesthesia, e.g. allergy to anaesthetics.
  26. pregnancy or breastfeeding.
  27. The patient does not sign an informed consent form.
  28. expected survival less than 1 year.
  29. The patient with poor compliance is not thought to complete follow-up visits.
  30. The patient is participating in an experimental drug or other device study with an incomplete primary endpoint, or the patient is participating in an unfinished experimental drug or other device study that would clinically interfere with our study endpoints.
  31. Due to other reasons the patient is not suitable for enrollment assessed by the researcher.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Observational model
Other
Time perspective
Prospective
Enrollment
160 participants (estimated)
Target follow-up
24 Months
Patient registry
Yes

Groups and cohorts

  • TEER group

    Severe DMR patients of low to intermediate surgery risk who underwent TEER.

    Diagnostic Test: ultrasonic cardiography (UCG) · Procedure: TEER

Interventions

  • Diagnostic testultrasonic cardiography (UCG)

    Trans-thoracic echocardiography (TTE) is performed in the resting position. Trans-esophageal echocardiography (TEE) is performed under surface anaesthesia with bupivacaine or intravenous anaesthesia. We comprehensively assess the severity of mitral regurgitation according to American Society of Echocardiography (ASE) guideline.

  • ProcedureTEER

    Two commercial cliping systems are available for clinical use: the G3 MitraclipTM and the G4 MitraclipTM (Abbott), DragonflyTM (Dejin), which will be introduced to the Chinese market in 2024, with the specific choice determined by the operator. The patient receives general anaesthesia (intravenous and endotracheal). The operator performs the procedure according to the recommended surgical steps in the product manual, guided by X-ray and trans-esophageal echocardiography. Postoperative MR ≤2+ is considered successful, and if the result is unsatisfactory, 1-2 additional clips are given.

06

What researchers measure

Primary outcomes

  1. cumulative composite event rate of the main adverse events

    The main adverse events: death, acute myocardial infarction, requiring secondary therapy for valve treatment failure, requiring non-scheduled cardiovascular emergency surgery for main complications, stroke, kidney failure, deep infection, \>48 hours mechanical ventilation, new-onset atrial fibrillation, deep vein thrombosis, pulmonary embolism, sepsis, haemorrhage, blood transfusion \>2U

    Time frame: time of operation to 30 days after operation

  2. cumulative composite event rate of all-cause death and worsening heart failure

    all-cause mortality: deaths from all causes including cardiovascular and non-cardiovascular deaths. worsening heart failure: heart failure rehospitalization, worsening heart failure needing emergency room visit, NYHA classification increased by one, ineffective escalation of medication on outpatient service, receiving intravenous diuretic therapy on outpatient or emergency service.

    Time frame: time of operation to 24 months after operation

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2024 (actual). Primary completion is estimated for Dec 2026, 35 months after the start.

Of 73 non-industry observational studies under Mitral Valve Insufficiency, half reached primary completion within 57 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 192. This study's planned 35 months is below that.

Counting every sponsor, half of 85 studies reached it within 57 months; a quarter within 26 and three quarters within 192.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 30, 2023
First posted
Dec 8, 2023
StartActual
Jan 1, 2024
Primary completionEst.
Dec 2026
CompletionEst.
Dec 2026
Last update
Mar 15, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 15, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06162780
Collaborators
Peking University Shenzhen Hospital, Dongguan People's Hospital, First People's Hospital of Foshan, The Second People's Hospital of Foshan, The First Affiliate Hospital of Guangxi Medical College, Affiliated Hospital of Guangdong Medical University, Huizhou The Third People's Hospital, Jiangmen Central Hospital, Guangzhou Panyu Center Hospital, Meizhou People's Hospital, Suzhou Municipal Hospital, The General Hospital of Southern Theater Command, People's Hospital of Nanhai District, Foshan, Nanfang Hosptial, China, Southern Medical University, China, First Affiliated Hospital of Shantou University Medical College, Shantou Central Hospital, Sichuan Provincial People's Hospital, First Affiliated Hospital Xi'an Jiaotong University, People's Hospital of Xinjiang Uygur Autonomous Region, Yueyang Central Hospital, ZhuZhou Central Hospital, First Affiliated Hospital, Sun Yat-Sen University, Third Affiliated Hospital, Sun Yat-Sen University, Fifth Affiliated Hospital, Sun Yat-Sen University, Central South University Xiangya Hospital, Zhongshan People's Hospital, Guangdong, China, Foshan Fosun Chancheng Hospital
Responsible party
Yangxin Chen (Chief physician, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University) — Principal investigator
First posted
Dec 8, 2023
Start date
Jan 1, 2024
Primary completion
Dec 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Mar 15, 2024

Study contacts

Yangxin Chen, PhD
Contact
chenyx39@mail.sysu.edu.cn
8681332360
Maohuan Lin
Contact
chenyx39@mail.sysu.edu.cn
8681332360
Yangxin Chen, PhD
principal investigator · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion